| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/16/2011 | EP2293818A2 Conjugates of a cholinesterase moiety and a polymer |
| 03/16/2011 | EP2293817A1 Stabilized liquid formulation |
| 03/16/2011 | EP2293791A1 Pharmaceutical compositions of entacapone co-micronized with sugar alcohols |
| 03/16/2011 | EP2293789A1 Novel depigmenting compositions in the form of a petroleum jelly-free and elastomer-free anhydrous composition comprising a solubilized phenolic derivative |
| 03/16/2011 | EP2293788A2 Novel depigmenting compositions in the form of a petroleum jelly-free and elastomer-free anhydrous composition comprising a solubilized phenolic derivative and a retinoid |
| 03/16/2011 | EP2293785A2 Nanoparticles containing a peptide, vectors containing the same and pharmaceutical uses of said nanoparticles and said vectors |
| 03/16/2011 | EP2293778A2 Composition comprising an antibiotic and a corticosteroid |
| 03/16/2011 | EP2293777A1 Pharmaceutical transdermal compositions and method for treating inflammation in cattle |
| 03/16/2011 | EP2293775A2 Hydrogel capable of containing and conveying cells |
| 03/16/2011 | EP2293771A2 Novel inverse latices that are free of oxyethylene derivatives, and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising same |
| 03/16/2011 | EP2293770A2 Novel inverse latices based on fatty alcohol ethers, and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising same |
| 03/16/2011 | EP2219665B1 Parathyroid hormone formulations and uses thereof |
| 03/16/2011 | EP2097453B1 Monoclonal antibodies against the human anti-müllerian hormone type ii receptor (amhr-ii) |
| 03/16/2011 | EP2083796B1 Metal coated nanoparticles for use in the treatment of enzymatic dermatitis |
| 03/16/2011 | EP1917976B1 Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration |
| 03/16/2011 | EP1551876B1 Antibodies that bind cell-associated ca 125/0722p and methods of use thereof |
| 03/16/2011 | EP1513507B1 Transdermal analgesic systems with reduced abuse potential |
| 03/16/2011 | EP1420762B1 Residual solvant extraction method and microparticles produced thereby |
| 03/16/2011 | EP1420010B1 Amphoteric lipid compound and use thereof |
| 03/16/2011 | EP1326633B1 Composition comprising immunogenic microparticles |
| 03/16/2011 | CN1994290B Transdermal plaster of rivastigmine and preparation process thereof |
| 03/16/2011 | CN101985478A Fusion protein and application thereof to ischemic brain stroke |
| 03/16/2011 | CN101985471A Folate-IgG conjugate as well as preparation method and application thereof |
| 03/16/2011 | CN101985470A Glucagon-like polypeptide-1 analog, preparation method and application thereof |
| 03/16/2011 | CN101985044A Taste-masking medicinal coating composition |
| 03/16/2011 | CN101985043A Method for improving water-solubility of insoluble drugs |
| 03/16/2011 | CN101984980A Extraction method, extract and pharmaceutical use of hypericum perforatum extract |
| 03/16/2011 | CN101984960A Rizatriptan benzoate capsule and preparation method thereof |
| 03/16/2011 | CN101984959A Freeze-dried powder injection for injecting brazilein and preparation method thereof |
| 03/16/2011 | CN101984956A Application of pH sensitive type amphiphilic graft polyphosphazene for preparing administration vesicle |
| 03/16/2011 | CN101984955A Method for preparing controlled release PVA |
| 03/16/2011 | CN101642453B Medicinal preparation comprising Epothilone B |
| 03/16/2011 | CN101618026B Meloxicam tablet, production technology and purposes thereof |
| 03/16/2011 | CN101613524B Triblock copolymer PEO-PPO-PEO/calcium phosphate nanometer composite material and preparation method thereof |
| 03/16/2011 | CN101590029B Propofol composition |
| 03/16/2011 | CN101590015B Cationic adhesion type mycophenolate mofetil nano eye drop |
| 03/16/2011 | CN101559038B Solid lipid nanoparticles of finasteride and preparation method thereof |
| 03/16/2011 | CN101491520B Local application medicine formulation |
| 03/16/2011 | CN101485749B Effervescent tablets for women as well as preparation method and application thereof |
| 03/16/2011 | CN101474155B Lung-targeted medicine carrying precursor liposome for injection and method of use thereof |
| 03/16/2011 | CN101468164B External targeted transdermal alkalescent blood-regulating agent and preparation method thereof |
| 03/16/2011 | CN101416956B Ambroxol hydrochloride injection |
| 03/16/2011 | CN101401786B Nelarabine injection |
| 03/16/2011 | CN101353475B Preparation of aquagel material having thermal sensitivity and reactivity |
| 03/16/2011 | CN101264130B Film coating agent for treating skin ulcer |
| 03/16/2011 | CN101244277B Medicine carrying fibroin microsphere and preparation thereof |
| 03/16/2011 | CN101209339B Wax candle with incense treating function and preparation method thereof |
| 03/16/2011 | CN101123991B Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| 03/16/2011 | CN101010067B Modafinil oral lyophilizate |
| 03/15/2011 | US7906664 Polyglycerol partial esters of polyricinoleic acid and polyfunctional carboxylic acids and the use thereof for producing emulsions and dispersions |
| 03/15/2011 | US7906628 Targeting proteins to deliver therapeutic or diagnostic reagents |
| 03/15/2011 | US7906545 Prodrugs of CC-1065 analogs |
| 03/15/2011 | US7906535 High concentration topical insecticides containing pyrethroids |
| 03/15/2011 | US7906477 Proteases of human kallikrein 2 (hK2); tissue imaging |
| 03/15/2011 | US7906145 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
| 03/15/2011 | US7906144 Solubilizing aids in powder form for solid pharmaceutical presentation forms |
| 03/15/2011 | US7906141 Sustained-release, oral pharmaceutical forms of formulation |
| 03/15/2011 | US7906139 phosphatidylcholine, sphingomyelin, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, and cholesterol; for removal of extra-/intra- vascular fibrin clots/adhesions; for use during surgery; for treatment of otitis |
| 03/15/2011 | US7906137 Delivery agents for enhancing mucosal absorption of therapeutic agents |
| 03/15/2011 | US7906135 Medical device comprising polyhydroxyalkanoate having pyrogen removed |
| 03/15/2011 | US7906128 Controlling parasites in animals by administerinng sodium channel activators |
| 03/15/2011 | US7906122 Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination |
| 03/15/2011 | US7906109 Pharmaceutical composition comprising an active principal and sulphobetaine |
| 03/15/2011 | CA2597154C Use of iron(iii) complex compounds |
| 03/15/2011 | CA2595003C Molecular aggregate capable of undergoing phase transition by dehydrating condensation and method of phase transition thereof |
| 03/15/2011 | CA2577740C Method of enhancing absorptions of transmucosal administration formulations |
| 03/15/2011 | CA2562982C Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 03/15/2011 | CA2502220C Transdermal patch for external use comprising fentanyl |
| 03/15/2011 | CA2496780C Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same |
| 03/15/2011 | CA2470703C Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| 03/15/2011 | CA2469174C Emulsifier for highly liquid w/o emulsions based on partly crosslinked polyglycerol esters of polyhydroxystearic acid |
| 03/15/2011 | CA2463681C Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent |
| 03/15/2011 | CA2443586C Methods of forming shaped articles from suspensions |
| 03/15/2011 | CA2443235C Pharmaceutical compositions comprising ascomycin |
| 03/15/2011 | CA2438426C Calcium supplementation to reduce prostate cancer risk |
| 03/15/2011 | CA2434169C Spaced drug delivery system |
| 03/15/2011 | CA2412776C Compositions controlling release ph range and/or speed |
| 03/15/2011 | CA2406064C Minimizing adverse experience associated with oxybutynin therapy |
| 03/15/2011 | CA2406008C Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
| 03/15/2011 | CA2404196C Medical emulsion for lubrication and delivery of drugs |
| 03/15/2011 | CA2389302C Delivery of proteins across polar epithelial cell layers |
| 03/15/2011 | CA2374398C Immunoconjugates having high binding affinity |
| 03/10/2011 | WO2011029028A2 Targeted delivery using tissue-specific peptidomimetic ligands |
| 03/10/2011 | WO2011028962A1 Antibody coformulations |
| 03/10/2011 | WO2011028875A1 Immunogenic conjugates for producing immune responses to drugs of abuse and methods of use |
| 03/10/2011 | WO2011028718A1 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 03/10/2011 | WO2011028629A1 Pharmaceutical formulations and methods of use |
| 03/10/2011 | WO2011028485A2 Tumoricidal, bactericidal, or viricidal macrophage activation |
| 03/10/2011 | WO2011028334A2 Synthesis and isolation of dendrimer systems |
| 03/10/2011 | WO2011028110A1 Composition for topical application, uses thereof, applicator device and kit of parts |
| 03/10/2011 | WO2011028016A2 Pharmaceutical preparation comprising beta-adrenergic blockers and angiotensin ii receptor blockers |
| 03/10/2011 | WO2011027786A1 Transdermally absorbable preparation |
| 03/10/2011 | WO2011027778A1 Composition for topical administration to eyes for use in treatment of ocular hypertension and glaucoma |
| 03/10/2011 | WO2011027729A1 Hydroxypropyl cellulose particles |
| 03/10/2011 | WO2011027728A1 Coating agent comprising hydroxyalkyl cellulose |
| 03/10/2011 | WO2011027605A1 Liquid composition to be filled in soft capsules |
| 03/10/2011 | WO2011027248A1 Oral liquid formulation comprising salbutamol and guaifenesin |
| 03/10/2011 | WO2011027152A1 Stable formulation of factor viii |
| 03/10/2011 | WO2011026898A2 Drug activation system |
| 03/10/2011 | WO2011026824A2 Novel diagnostic agents for the non-invasive in vivo imaging of aminopeptidase n (apn/cd13) |